drugset
drugset / Trial / NCT01363817

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT01363817 ↗

Phase 1 Completed 31 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies

Timeline

Start
2011-09-28
Primary completion
2018-02-07
Completion
2018-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AL101 Small molecule 0.3 mg Intravenous
Background Dexamethasone Small molecule 20 mg Oral

Indications

T-cell acute lymphoblastic leukemia T-lymphoblastic lymphoma